On June 4, 2021, semaglutide injection (2.4 mg, once a week) was officially approved by the United States Food and Drug Administration (FDA) for chronic weight management in obese or overweight adults. As an adjunct to lowering dietary calories and  increasing physical activity for long-term weight management in eligible adults with an initial body mass index (BMI).

Including: (1) BMI≥30kg/m2 (obesity); (2) BMI ≥ 27kg/m2 (overweight) with at least one weight-related complication (such as hypertension, type 2 diabetes, or dyslipidemia).However, it should be noted that semaglutide has not been approved for weight loss in China. There are the following indications in China:

01

Glycemic control in adults with type 2 diabetes: treatment of adults with type 2 diabetes who still have poor glycemic control on the basis of diet and exercise, metformin and/or sulfonylureas;

02

It is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus with cardiovascular disease.

At the same time, because the dose of semaglutide for weight loss is much larger than the dose for the treatment of diabetes, the specification of semaglutide marketed in China is small (the maximum dose is 1mg), which may not enable users to achieve significant weight loss.

The information is from the Internet and is for reference only.